KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Esperion Therapeutics (ESPR) Operating Expenses (2016 - 2026)

Esperion Therapeutics filings provide 8 years of Operating Expenses readings, the most recent being -$130.4 million for Q4 2025.

  • On a quarterly basis, Operating Expenses fell 277.37% to -$130.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $129.2 million, a 53.5% decrease, with the full-year FY2025 number at $129.2 million, down 53.5% from a year prior.
  • Operating Expenses hit -$130.4 million in Q4 2025 for Esperion Therapeutics, down from $97.3 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $97.3 million in Q3 2025 to a low of -$130.4 million in Q4 2025.
  • Median Operating Expenses over the past 5 years was $71.1 million (2021), compared with a mean of $62.0 million.
  • The widest YoY moves for Operating Expenses: up 43.76% in 2025, down 277.37% in 2025.
  • Esperion Therapeutics' Operating Expenses stood at $71.0 million in 2021, then fell by 13.65% to $61.3 million in 2022, then rose by 21.66% to $74.6 million in 2023, then dropped by 1.45% to $73.5 million in 2024, then tumbled by 277.37% to -$130.4 million in 2025.
  • The last three reported values for Operating Expenses were -$130.4 million (Q4 2025), $97.3 million (Q3 2025), and $75.3 million (Q2 2025) per Business Quant data.